title: [A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment].
abstract: 250 patients suffering from pulmonary tuberculosis who were smear positive received a chemotherapy regime for 6 months combining Rifampicin and Isoniazid every day with a daily supplement of Pyrazinamide for the first 8 weeks. The three drugs given in the initial phase of treatment were administered either separately or in combined preparations according to the 2 controlled randomised groups. During the maintenance phase the drugs were given in a combined form in fixed proportions in the 2 groups. 6 months after the end of treatment the bacteriological results were similar in the 2 groups in the 144 cases which were analysed. Amongst 137 cases with bacilli which were initially sensitive to Isoniazid (68 cases with separate medicines at the beginning and 69 with combined drugs) there was no failure at 6 months, nor any relapse during the course of the first period of surveillance. Amongst 7 cases with bacilli which were originally resistant to Isoniazid (4 and 3 respectively), there were 2 failures at 6 months one in each group with acquired resistance to Rifampicin observed at the time of the failure. There was no difference in the therapeutic results observed whatever the presentation of drugs used during the initial phase of treatment.
authors.affiliation: Clinique Matiben, Hôpital de Béni-Messous, Centre Hospitalier Universitaire d'Alger-Ouest, Algérie.
authors.forename: D
authors.initials: D
authors.lastname: Agounitestane
authors.forename: M
authors.initials: M
authors.lastname: Chiheb
authors.forename: S
authors.initials: S
authors.lastname: Khaled
authors.forename: N
authors.initials: N
authors.lastname: Ait Khaled
authors.forename: F
authors.initials: F
authors.lastname: Boulahbal
authors.forename: P
authors.initials: P
authors.lastname: Chaulet
mesh_terms: D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D005500:Follow-Up Studies; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use*; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D004338:Drug Combinations; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin
vernacular_title: Essai thérapeutique d'une combinaison de trois médicaments essentiels dans la chimiothérapie courte de la tuberculose. Résultats six mois après la fin du traitement.